$800 million to stop team-killing in your immune system
Genentech, a subsidiary of the Roche Group, partnered with Parvus Therapeutics to develop Navacim‚Ñ¢ Therapeutics for the treatment of autoimmune diseases. Parvus Therapeutics will receive $800 million in the form of upfront and milestone payments, as well as royalties on net sales. Roche‘s most recent patent publication in the AI Biotech sector is directed to continuously monitoring glucose levels for helping patients with diabetes, an autoimmune disease.
Related Posts
Cala Health Claims to Have the only Patented Neurostimulation for Essential Tremor Treatment. The Patent Data Disagrees
Cala Health has figured out that innovations backed by patents make them exponentially more valuable in the marketplace. However, in a zest…
Capital One is Investing in AI Biotech? What’s in their wallet?
In the past 18 months, Capital One has expanded past its usual banking activities, and begun exploring the AI Biotech Sector. But do they…
Google AI Reinvents Speech Recognition. Who will follow?
There is no doubt that the big 5 tech companies (Apple, Amazon, Google, Facebook, and Microsoft) have developed massive IP portfolios in…